Reynolds American Inc. (NYSE: RAI) has an interesting approach in M&A today. The deal is a tiny merger valued at $44 million when you consider that Reynolds has almost a $15 billion market cap, but this is a potential game-changer in tobacco. The company is acquiring all outstanding shares of the Swedish-based nicotine replacement therapy [[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Posts Tagged drug companies
We may have had earnings season officially start with Alcoa this week, but next week will be the real week for the launch of earnings season. We now have an index to track the top 500 companies by market cap on a real-time basis via the 24/7 Wall St. Real-Time 500, and these top 10 [[ This is a content summary only
If you can’t take the heat, get out of the kitchen. That is what Citigroup, Inc. (NYSE: C) has done over its Phibro commodities trading unit. Occidental Petroleum Corporation (NYSE: OXY) has signed an agreement to acquire Phibro LLC from Citi “for approximately net asset value.” Interestingly enough, that net asset value was not disclosed, [[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Fidelity Management & Research Company, or FMR, was among the giants which released its quarterly holdings over the most recent days. While it is always interesting to see which holdings are the top holdings, most traders look at the big portfolio changes to try to gain insight into the minds of fund managers. We looked [[ This is a content summary only
Diabetes is becoming an epidemic in the U.S. and the Western World. The ties to obesity are often direct, so the potential treatments are often directly tied as well. We did a recent dig down for the next $170 billion opportunity for eight different major diseases and conditions, and now we have conducted a much [[ This is a content summary only.
MannKind Corporation (NASDAQ: MNKD) is getting hit after the company announced that it priced a secondary offering of 7,400,000 shares of its common stock. While the press release does not say what price the deal came at, the syndicate group told us this went out at $7.35 per share. The company’s chairman, CEO, and principal [[ This is a content summary only. Visit my website for full links, other content, and more! ]]
It is an audacious statement, but Sir Liam Donaldson, Chief Medical Officer of the UK, believes that swine flu cases may have peaked at about 110,000. He sees evidence that the number of people contracting the disease has leveled off
Deflation Emerges With Force
Jul 31
The Fed has stated that it is not worried that low interest rates and an economic recovery will cause inflation. Adjustments in economic policy and control of the money supply will prevent that. Deflation is another matter.
Safety and efficacy data are critical to drug candidates. But what really makes a potential drug attractive is strong top-line data, a new biotech-based treatment, and a massive potential market. With help from Thomson Reuters’ SD Pharma database and our own backlog of coverage, BioHealthInvestor.com, a 247wallst.com website, sought to find the most promising biopharmaceutical candidate from both [[ This is a content summary only.
Here are some of the top stories affecting key drug and biotech stocks that have links through to more in-depth coverage and analysis today at the website BioHealthInvestor.com: Rigel Pharmaceuticals Inc.’s (NASDAQ: RIGL) Phase IIb trial results Thursday morning of its rheumatoid arthritis candidate R788, is boosting its stock on speculation it may help the company [[ This is a content summary only. Visit my website for full links, other content, and more! ]]
